Drug Trial Radar · NCT04647773
To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain
Last checked: Nov 20, 2026Latest source record: Dec 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
687
Planned (sponsor's estimate)
Start
Dec 2, 2020
Primary completion
Nov 9, 2022
Study completion Nov 16, 2022
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigate the efficacy and safety of HSK16149 capsules in Chinese diabetic peripheral neuropathic pain (DPNP) following 13 weeks treatment in comparison to placebo.
Conditions
- Diabetic Peripheral Neuropathic Pain
Interventions
HSK16149 20mg BIDDrug
HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
HSK16149 40mg BIDDrug
HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
HSK16149 60mg BIDDrug
HSK16149 60mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
HSK16149 80mg BIDDrug
HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
Pregabalin 150mg BIDDrug
Pregabalin 150mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
Placebo BIDDrug
Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the change from baseline in Average Daily Pain Score(ADPS) between HSK16149 and placebo at week 5.Time frame: Baseline and week 5
- Compare the change from baseline in Average Daily Pain Score (ADPS) between HSK16149 and placebo at week 13.Time frame: Baseline and week 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.